Living with obesity and metabolic dysfunction can be extremely difficult and frustrating for patients. Did you know that millions of people suffer from weight-related metabolic conditions every year? In some cases, the condition can be so severe that it limits a person’s ability to function normally, leaving clinicians searching for accessible pharmacotherapy options. When major pharmacy benefit managers restrict access, your clinic workflow is disrupted by endless prior authorization appeals, and your patients are left waiting for care. This delay can resist patients from starting their treatment.
However, the recent CVS GLP-1 formulary update has completely shifted the prescribing environment for 2026. CVS has officially restored coverage for Eli Lilly’s Zepbound after previous formulary restrictions made it incredibly difficult to obtain. What’s more, the newly FDA-approved oral GLP-1, Foundayo, also known as orforglipron, has been immediately added to CVS formularies. This dual-addition signals a major shift in PBM willingness to cover obesity management pipelines. It improves patient access but also requires updated clinic protocols to manage the new demand. In this blog post, we will discuss the implications of the CVS GLP-1 formulary update, the clinical efficacy of Foundayo, and how you can handle the resumed Zepbound prior authorizations without bottlenecking your practice.
What triggered the CVS GLP-1 formulary update?
The field of obesity treatment has seen a massive surge in patient demand over the past few years. If you are wondering why pharmacy benefit managers restricted access to these medications in the first place, it primarily came down to managing soaring costs amidst an explosion of off-label prescribing for aesthetic weight loss. However, the sheer volume of clinical evidence supporting weight loss as a primary health intervention has made it impossible for insurance companies to ignore any longer. The recent CVS GLP-1 formulary update is a direct response to this growing body of peer-reviewed data and the immense pressure from both patients and healthcare providers.
The shift in PBM strategy and cost management
With the FDA approval of Foundayo, CVS had a unique opportunity to introduce a daily oral medication into their tiered coverage model. Unlike the injectable peptides that require complex cold-chain logistics and specialized manufacturing, an oral small-molecule GLP-1 receptor agonist offers a much more streamlined supply chain. This makes it easier and potentially more cost-effective to distribute on a massive scale.
The decision to restore Zepbound alongside Foundayo suggests that CVS is now willing to support an all-rounded obesity management pipeline rather than just restricting access to the cheapest options. This dual-addition improves patient access significantly for those who truly need the medication for metabolic health.
However, you will have to update your clinic workflows to handle the influx of patients asking for these specific brand names. Your front office staff must be prepared for the documentation requirements that accompany this formulary shift. The demand is not going away anytime soon, so getting your clinic protocols in order is an essential step.
Understanding Foundayo and oral GLP-1 options
Foundayo is an oral small-molecule GLP-1 receptor agonist designed specifically for obesity treatment. Many patients are hesitant to start injectable therapies due to a severe fear of needles or simply the inconvenience of remembering a weekly shot. In that case, you can offer them an oral alternative that delivers comparable metabolic benefits without the anxiety of self-injection. Orforglipron is a non-peptide agonist. This means it does not get destroyed by stomach enzymes the way traditional peptide-based drugs do, allowing it to be absorbed effectively through the digestive tract.
The exact mechanism of non-peptide agonism
The pharmacological basis for non-peptide agonism of the GLP-1 receptor by orforglipron is quite unique. According to Sloop et al in Science Translational Medicine 2024, the molecule binds to a completely distinct site on the GLP-1 receptor compared to native GLP-1 or other peptide analogs. This specific binding triggers the receptor to activate intracellular signaling pathways that promote insulin secretion and significantly slow gastric emptying. It helps treat various conditions related to excess weight by making the patient feel full much faster.
The gut hormones play an essential role in appetite regulation, as clearly noted by Hong et al in Current Opinion in Endocrinology, Diabetes, and Obesity 2024. By mimicking the action of these natural hormones, Foundayo sends powerful and sustained satiety signals directly to the brain. There is a complex inter-organ neural circuit for appetite suppression, which was detailed by Zhang et al in Cell 2022. This neural circuit is heavily influenced by these receptor agonists, shutting down the constant food noise that many obese patients struggle with daily.
Clinical efficacy of orforglipron in recent trials
When discussing new medications with your patients, you need to know exactly how well they work in the real world. The clinical trial data for orforglipron is highly encouraging and gives clinicians a solid foundation for prescribing it. In a landmark study published by Wharton et al in The New England Journal of Medicine 2023, adults with obesity taking a daily oral dose of orforglipron saw substantial weight reductions over a thirty-six-week period.
Significant weight reduction outcomes
Patients taking the higher doses of the medication experienced some best ever results that rivaled the early injectable GLP-1 therapies. Wharton et al followed up with another publication in The New England Journal of Medicine in 2025, reaffirming that orforglipron is a highly effective oral small-molecule GLP-1 receptor agonist for obesity treatment.
Lütkemeyer et al confirmed these exact effects in their 2024 systematic review and meta-analysis published in Archives of Endocrinology and Metabolism. They found that once-daily oral orforglipron significantly reduced both body weight and essential metabolic markers across multiple randomized controlled trials. In the treatment groups, patients lost a considerable amount of weight compared to those on a placebo.
Besides this, the improvements in cardiometabolic parameters were distinct and measurable. Dutta et al also highlighted in Obesity Science & Practice 2024 that this novel non-peptide oral medicine is a highly effective anti-obesity agent. The proportion of patients achieving clinically meaningful weight loss was much higher in the orforglipron groups compared to the control groups. This makes it an all-rounded solution for patients who need aggressive weight management but refuse to take injections under any circumstances.
How does Zepbound fit back into the picture?
With Foundayo taking the spotlight as an exciting new oral option, you might be wondering where Zepbound fits into your prescribing habits now. Zepbound, known generically as tirzepatide, remains one of the most potent and effective injectable weight loss medications available on the market today. The recent CVS GLP-1 formulary update successfully restored coverage for Zepbound. This means your patients who require a powerful dual GIP and GLP-1 receptor agonist can once again access it through their standard pharmacy benefits.
The power of multiplexed pharmacological actions
Tirzepatide works quite differently than standard GLP-1 agonists. It has multiplexed pharmacological actions at both the GIP and GLP-1 receptors. This dual-receptor mechanism was explored in depth by Zhao et al in Nature Communications 2022. This dual action provides profound weight loss and a deep metabolic correction that single-receptor agonists sometimes fail to achieve.
Xie et al in Metabolism: Clinical and Experimental 2024 conducted an updated network meta-analysis of seven GLP-1 receptor agonists and polyagonists. They confirmed that tirzepatide consistently ranks at the very top for total weight reduction in patients with obesity or overweight.
For patients with severe obesity, or those who have simply not reached their target goals on a single-receptor agonist, Zepbound is an essential tool in your clinical arsenal. Your doctor will likely start with a lower dose and slowly titrate up over several months. This slow titration helps to manage common gastrointestinal side effects, such as nausea, vomiting, indigestion, and other health problems.
Are there broader metabolic impacts and cancer risks?
Weight loss is only one piece of the puzzle when you prescribe a GLP-1 receptor agonist to a patient. The broader metabolic benefits are what truly make these drugs so incredibly valuable for long-term health and longevity. However, if you want to provide truly all-rounded care to your patients, you must be fully aware of the recent clinical data regarding obesity-associated cancers.
Massive cancer risk reduction
Obesity is a well-known driver for numerous types of dangerous malignancies. Wang et al investigated this specific link in JAMA Network Open 2024, looking closely at GLP-1 receptor agonists and thirteen different obesity-associated cancers in patients with type 2 diabetes. They found that patients taking these medications had a significantly lower risk of developing these specific cancers compared to those who were only taking older, traditional diabetes drugs.
Another study by Wang et al in JAMA Oncology 2024 focused specifically on colorectal cancer risk. They discovered that GLP-1 receptor agonists drastically reduced the risk of colorectal cancer in drug-naive patients with type 2 diabetes. This protective effect was seen regardless of whether the patients were formally classified as overweight or obese.
This is an incredible secondary benefit that you can discuss with your patients. Yes, the primary goal of the treatment is always weight reduction. However, protecting your patients from aggressive, obesity-driven cancers makes these medications an all-rounded approach to preventive medicine. You can use this compelling data to encourage adherence in patients who might be struggling with minor side effects during the first few weeks of treatment.
What are the real-world limitations of these therapies?
While the clinical trial numbers look fantastic on paper, everyday clinical practice often presents a more complicated picture. The CVS GLP-1 formulary update provides access, but it does not guarantee that every single patient will tolerate the medication. Nong et al discussed the broad spectrum of medications for adults with type 2 diabetes in their 2025 living systematic review published in the BMJ. They noted that while GLP-1 agonists are highly effective, the real-world discontinuation rates due to gastrointestinal intolerance remain a significant clinical hurdle.
Managing patient expectations and side effects
Patients often read the headlines and expect immediate, side-effect-free weight loss. However, you will have to manage their expectations carefully from day one. Krinsky et al reviewed oral GLP-1 receptor agonists for weight loss in Cardiology in Review 2024, highlighting that while the oral route improves convenience, the gastrointestinal side effect profile is very similar to the injectable versions. Nausea, diarrhea, and abdominal pain are common reasons patients stop taking the drug entirely.
Besides this, Kokkorakis et al emphasized in Pharmacological Reviews 2025 that emerging pharmacotherapies for obesity still require long-term adherence to maintain the weight loss. If a patient stops taking Foundayo or Zepbound because they cannot afford the copay or cannot tolerate the nausea, the weight will almost certainly return. This is a massive limitation in real-world settings. Your clinical strategy must include continuous dietary counseling, resistance training to preserve lean muscle mass, and proactive management of side effects to keep the patient on the therapy long-term.
Can AI help predict patient response to treatment?
The entire field of obesity medicine is advancing at a rapid pace, and artificial intelligence is slowly beginning to play a role in how we manage these complex therapies. If you are wondering how AI actually fits into an everyday clinical practice, it primarily revolves around predicting which specific patient will respond best to which medication before they even take the first dose.
Utilizing unique metabolic variability signatures
It is a well-known fact that not all patients respond to GLP-1 agonists in the exact same way. Some patients experience rapid, almost effortless weight loss, while others see only very modest changes after months of treatment. Landau et al discussed this complex issue in Biomedicines 2025, where they explored employing an artificial intelligence platform to enhance treatment responses to GLP-1 agonists.
The system utilizes specific metabolic variability signatures based on the constrained disorder principle. Essentially, the AI system analyzes a patient’s unique metabolic fluctuations to accurately predict their weight loss trajectory on the medication. This kind of advanced technology could eventually help you decide whether a patient should go for the oral Foundayo or go straight to the more potent injectable Zepbound.
While this specific AI platform might not be available in every single clinic today, it strongly represents the future of personalized obesity medicine. It helps treat the individual patient’s unique biology rather than relying on a slow process of trial and error.
Strategies for handling the new prior authorization workflows
The immediate addition of Foundayo and the welcome restoration of Zepbound are undoubtedly great news for patient access across the country. However, you will still have to deal with the harsh administrative reality of prior authorizations on a daily basis. CVS has updated their formularies to include these drugs, but they still require highly detailed clinical documentation to actually approve these high-cost medications for your patients.
Streamlining your clinic protocols
Your front office staff must be incredibly proactive to avoid massive clinic bottlenecks. You should clearly document the patient’s starting body mass index, any weight-related comorbidities they suffer from, and their extensive history of lifestyle interventions. When prescribing Zepbound, you must explicitly note any previous failures on lower-tier weight loss drugs. For Foundayo, it is helpful to highlight the patient’s strong preference or medical need for an oral medication over an injectable one.
If you take the time to set up standardized templates in your electronic health record for these specific drugs, you can speed up the approval process significantly for everyone involved. Dealing with prior authorizations can be incredibly frustrating and time-consuming. However, if you follow these simple organizational steps, you can rest assured that the paperwork will go much more smoothly. Your patients rely on you to handle this process efficiently so they can start their prescribed treatment without unnecessary and frustrating delays.
Conclusion
Undoubtedly, the field of obesity management is changing for the better with the recent CVS GLP-1 formulary update. If you have suffered from the administrative headaches of restricted access, this shift brings some much-needed relief. Millions of people struggle with obesity and its related metabolic complications, and they need reliable access to effective medications.
The addition of oral Foundayo and the return of Zepbound to the formulary mean that you now have powerful tools available for your patients. While there is no specific cure for the chronic nature of obesity, it can be managed highly effectively with the right pharmacological approach.
By updating your clinic workflows and staying informed on the latest clinical data, you can improve your patients’ symptoms and quality of life. The prior authorization process may still require some effort, but you can rest assured that the path to approval is clearer than it has been in years.
References
- Kokkorakis M et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological reviews 2025. doi:10.1124/pharmrev.123.001045 (PMID: 39952695)
- Xie Z et al. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism: clinical and experimental 2024. doi:10.1016/j.metabol.2024.156038 (PMID: 39305981)
- Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England journal of medicine 2025. doi:10.1056/NEJMoa2511774 (PMID: 40960239)
- Wharton S et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. The New England journal of medicine 2023. doi:10.1056/NEJMoa2302392 (PMID: 37351564)
- Hong SH et al. Gut hormones and appetite regulation. Current opinion in endocrinology, diabetes, and obesity 2024. doi:10.1097/MED.0000000000000859 (PMID: 38511400)
- Sloop KW et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Science translational medicine 2024. doi:10.1126/scitranslmed.adp5765 (PMID: 39693407)
- Lütkemeyer C et al. Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials. Archives of endocrinology and metabolism 2024. doi:10.20945/2359-4292-2023-0469 (PMID: 39420937)
- Dutta D et al. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obesity science & practice 2024. doi:10.1002/osp4.743 (PMID: 38414573)
- Krinsky D et al. Oral GLP-1 Receptor Agonists for Weight Loss. Cardiology in review 2024. doi:10.1097/CRD.0000000000000833 (PMID: 39688941)
- Nong K et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ (Clinical research ed.) 2025. doi:10.1136/bmj-2024-083039 (PMID: 40813122)
- Zhang T et al. An inter-organ neural circuit for appetite suppression. Cell 2022. doi:10.1016/j.cell.2022.05.007 (PMID: 35662413)
- Wang L et al. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA network open 2024. doi:10.1001/jamanetworkopen.2024.21305 (PMID: 38967919)
- Landau J et al. Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder Principle. Biomedicines 2025. doi:10.3390/biomedicines13112645 (PMID: 41301738)
- Zhao F et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nature communications 2022. doi:10.1038/s41467-022-28683-0 (PMID: 35217653)
- Wang L et al. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA oncology 2024. doi:10.1001/jamaoncol.2023.5573 (PMID: 38060218)
- https://www.fiercehealthcare.com/pharma/cvs-restores-coverage-eli-lilly-obesity-drugs-zepbound-foundayo
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
